JP2018515612A - 置換キノキサリン誘導体 - Google Patents
置換キノキサリン誘導体 Download PDFInfo
- Publication number
- JP2018515612A JP2018515612A JP2018511333A JP2018511333A JP2018515612A JP 2018515612 A JP2018515612 A JP 2018515612A JP 2018511333 A JP2018511333 A JP 2018511333A JP 2018511333 A JP2018511333 A JP 2018511333A JP 2018515612 A JP2018515612 A JP 2018515612A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- quinoxalin
- indol
- amine
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C(*)*c(cc1*)cc2c1nc(*)c(*)n2 Chemical compound *C(*)*c(cc1*)cc2c1nc(*)c(*)n2 0.000 description 34
- FZONISRUVPVLJC-UHFFFAOYSA-N Cc(cc1Cl)cc2c1nccn2 Chemical compound Cc(cc1Cl)cc2c1nccn2 FZONISRUVPVLJC-UHFFFAOYSA-N 0.000 description 2
- UQGNSLYYFIRZOM-UHFFFAOYSA-N Brc1ccc(cc[n]2Cc3ccccc3)c2c1 Chemical compound Brc1ccc(cc[n]2Cc3ccccc3)c2c1 UQGNSLYYFIRZOM-UHFFFAOYSA-N 0.000 description 1
- DDRIHMDLLYDZBD-PLNGDYQASA-N C/C=C\c(c(C)c1)ccc1-c1cc(C)cc2c1nccn2 Chemical compound C/C=C\c(c(C)c1)ccc1-c1cc(C)cc2c1nccn2 DDRIHMDLLYDZBD-PLNGDYQASA-N 0.000 description 1
- LWULOCJOCRWMGM-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(c1cccnc1)Nc(cc1Cl)cc2c1nccn2)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(c1cccnc1)Nc(cc1Cl)cc2c1nccn2)=O LWULOCJOCRWMGM-UHFFFAOYSA-N 0.000 description 1
- PUAFCAJTMHPGBY-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(c1cccnc1)Nc1cc(I)c2nccnc2c1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(c1cccnc1)Nc1cc(I)c2nccnc2c1)=O PUAFCAJTMHPGBY-UHFFFAOYSA-N 0.000 description 1
- FXEXBMCNCCBCPX-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1)CC1C(c1cccnc1)=O)=O Chemical compound CC(C)(C)OC(N(CCC1)CC1C(c1cccnc1)=O)=O FXEXBMCNCCBCPX-UHFFFAOYSA-N 0.000 description 1
- IQMLWGPUGRBCNZ-UHFFFAOYSA-N CC(C)C(N1CC(Cc(cc2-c3ccc(C=C[I]4C)c4c3)cc3c2nccn3)CC1)=O Chemical compound CC(C)C(N1CC(Cc(cc2-c3ccc(C=C[I]4C)c4c3)cc3c2nccn3)CC1)=O IQMLWGPUGRBCNZ-UHFFFAOYSA-N 0.000 description 1
- NNOWOSKMCDUBMG-UHFFFAOYSA-N CC(C)[n]1c2cc(B3OC(C)(C)C(C)(C)O3)ccc2cc1 Chemical compound CC(C)[n]1c2cc(B3OC(C)(C)C(C)(C)O3)ccc2cc1 NNOWOSKMCDUBMG-UHFFFAOYSA-N 0.000 description 1
- NCXMZDJMHIECQF-UHFFFAOYSA-N CC(N(C1)CC1C(c1cnccc1)N)=O Chemical compound CC(N(C1)CC1C(c1cnccc1)N)=O NCXMZDJMHIECQF-UHFFFAOYSA-N 0.000 description 1
- FYVAXSUPDZBRHT-UHFFFAOYSA-N CC(N(C1)CC1Nc1cc(-c2ccc(cc[n]3C)c3c2)c2nccnc2c1)=O Chemical compound CC(N(C1)CC1Nc1cc(-c2ccc(cc[n]3C)c3c2)c2nccnc2c1)=O FYVAXSUPDZBRHT-UHFFFAOYSA-N 0.000 description 1
- RWIQLUBSUFVWPL-UHFFFAOYSA-N CC(N(CC1)CCC1C(Cc(cc1-c2ccc(cc[n]3C[I]=C)c3c2)cc2c1nccn2)c1c(C=[IH])ccnc1)=O Chemical compound CC(N(CC1)CCC1C(Cc(cc1-c2ccc(cc[n]3C[I]=C)c3c2)cc2c1nccn2)c1c(C=[IH])ccnc1)=O RWIQLUBSUFVWPL-UHFFFAOYSA-N 0.000 description 1
- HIVZUWNBNOTGHZ-UHFFFAOYSA-N CC(N(CC1)CCC1C(c1cccnc1)Nc(cc1-c2ccc3[s]c(N)nc3c2)cc2c1nccn2)=O Chemical compound CC(N(CC1)CCC1C(c1cccnc1)Nc(cc1-c2ccc3[s]c(N)nc3c2)cc2c1nccn2)=O HIVZUWNBNOTGHZ-UHFFFAOYSA-N 0.000 description 1
- OAUFZGQHZUOSSI-UHFFFAOYSA-N CC(N(CC1)CCC1C(c1cccnc1)Nc(cc1Cl)cc2c1nccn2)=O Chemical compound CC(N(CC1)CCC1C(c1cccnc1)Nc(cc1Cl)cc2c1nccn2)=O OAUFZGQHZUOSSI-UHFFFAOYSA-N 0.000 description 1
- GVXMHRWETMLFGH-UHFFFAOYSA-N CC(N(CC1)CCC1C(c1cnccc1)Nc(cc1-c(cc2)ccc2Br)cc2c1nccn2)=O Chemical compound CC(N(CC1)CCC1C(c1cnccc1)Nc(cc1-c(cc2)ccc2Br)cc2c1nccn2)=O GVXMHRWETMLFGH-UHFFFAOYSA-N 0.000 description 1
- KHTYIBJAILQVMK-UHFFFAOYSA-N CC(N(CC1)CCC1Nc(cc1-c2cc([n](Cc3ccccc3)cc3)c3cc2)cc2c1N=CCN2)=O Chemical compound CC(N(CC1)CCC1Nc(cc1-c2cc([n](Cc3ccccc3)cc3)c3cc2)cc2c1N=CCN2)=O KHTYIBJAILQVMK-UHFFFAOYSA-N 0.000 description 1
- JNPVOZGLJKRAOW-UHFFFAOYSA-N CC(N(CC1)CCC1Nc(cc1-c2ccc3nc[nH]c3c2)cc2c1nccn2)=O Chemical compound CC(N(CC1)CCC1Nc(cc1-c2ccc3nc[nH]c3c2)cc2c1nccn2)=O JNPVOZGLJKRAOW-UHFFFAOYSA-N 0.000 description 1
- OURKFZKDMOHUEO-UHFFFAOYSA-N CC(N(CC1)CCC1Nc1cc(nccc2C)c2c(-c2ccc(CCN3C)c3c2)c1)=O Chemical compound CC(N(CC1)CCC1Nc1cc(nccc2C)c2c(-c2ccc(CCN3C)c3c2)c1)=O OURKFZKDMOHUEO-UHFFFAOYSA-N 0.000 description 1
- QEWORNFRVUKEMC-GOSISDBHSA-N CC(N(CC1)C[C@@H]1C(c(cc1-c2ccc(cc[n]3C)c3c2)cc2c1nccn2)=N)=O Chemical compound CC(N(CC1)C[C@@H]1C(c(cc1-c2ccc(cc[n]3C)c3c2)cc2c1nccn2)=N)=O QEWORNFRVUKEMC-GOSISDBHSA-N 0.000 description 1
- CWJVKWBWJNRSFQ-SFHVURJKSA-N CC(N(CC1)C[C@H]1C(c1cc(N=CCC2)c2c(-c2ccc(C)c(NC)c2)c1)=N)=O Chemical compound CC(N(CC1)C[C@H]1C(c1cc(N=CCC2)c2c(-c2ccc(C)c(NC)c2)c1)=N)=O CWJVKWBWJNRSFQ-SFHVURJKSA-N 0.000 description 1
- JKSUKBSXQYZPQF-NRFANRHFSA-N CC(N(CC1)C[C@H]1Nc1cc(cccc2)c2c(-c2ccc3NCCCN(C)c3c2)c1)=O Chemical compound CC(N(CC1)C[C@H]1Nc1cc(cccc2)c2c(-c2ccc3NCCCN(C)c3c2)c1)=O JKSUKBSXQYZPQF-NRFANRHFSA-N 0.000 description 1
- UOBLHNSVJPQDNB-HOINCLMKSA-N CC(N(CCC1)CC1[C@@H](c1cccnc1)Nc(cc1-c2ccc(cc[n]3C)c3c2)cc2c1nccn2)=O Chemical compound CC(N(CCC1)CC1[C@@H](c1cccnc1)Nc(cc1-c2ccc(cc[n]3C)c3c2)cc2c1nccn2)=O UOBLHNSVJPQDNB-HOINCLMKSA-N 0.000 description 1
- UOBLHNSVJPQDNB-PEFOLFAWSA-N CC(N(CCC1)CC1[C@H](c1cnccc1)Nc(cc1-c2ccc(cc[n]3C)c3c2)cc2c1nccn2)=O Chemical compound CC(N(CCC1)CC1[C@H](c1cnccc1)Nc(cc1-c2ccc(cc[n]3C)c3c2)cc2c1nccn2)=O UOBLHNSVJPQDNB-PEFOLFAWSA-N 0.000 description 1
- QFSQQQQUALKAHZ-UHFFFAOYSA-N CC(N1CCC(CCc(cc2-c3ccc(cc[nH]4)c4c3)cc3c2nccn3)CC1)=O Chemical compound CC(N1CCC(CCc(cc2-c3ccc(cc[nH]4)c4c3)cc3c2nccn3)CC1)=O QFSQQQQUALKAHZ-UHFFFAOYSA-N 0.000 description 1
- AVGWRZUXOXOSNO-UHFFFAOYSA-N CC(NC(CC1)CCC1C(c1cccnc1)=O)=O Chemical compound CC(NC(CC1)CCC1C(c1cccnc1)=O)=O AVGWRZUXOXOSNO-UHFFFAOYSA-N 0.000 description 1
- QXLCAQKXZSBGER-WVRLJUPJSA-N CC/C(/C=C(/C=C(C=C1)c2cc(/C=C/C(CC3)CCN3C(C)=O)cc3c2CC=CC=N3)\C1=C)=C/C Chemical compound CC/C(/C=C(/C=C(C=C1)c2cc(/C=C/C(CC3)CCN3C(C)=O)cc3c2CC=CC=N3)\C1=C)=C/C QXLCAQKXZSBGER-WVRLJUPJSA-N 0.000 description 1
- ZJVGZQOSLAZPOI-UHFFFAOYSA-N CC1(C)OB(c2ccc3[n](Cc4ccccc4)ccc3c2)OC1(C)C Chemical compound CC1(C)OB(c2ccc3[n](Cc4ccccc4)ccc3c2)OC1(C)C ZJVGZQOSLAZPOI-UHFFFAOYSA-N 0.000 description 1
- JKYOFTXMXLLONP-UHFFFAOYSA-N CC1CCc2cc(B3OC(C)(C)C(C)(C)O3)ccc2CCC1 Chemical compound CC1CCc2cc(B3OC(C)(C)C(C)(C)O3)ccc2CCC1 JKYOFTXMXLLONP-UHFFFAOYSA-N 0.000 description 1
- XLLOEYQVTCCGSL-UHFFFAOYSA-N CC1N=C(C=CC(c2cc(Cl)cc3c2nccn3)=C2)C2=C1 Chemical compound CC1N=C(C=CC(c2cc(Cl)cc3c2nccn3)=C2)C2=C1 XLLOEYQVTCCGSL-UHFFFAOYSA-N 0.000 description 1
- LPIRIXGJDXJEFW-UHFFFAOYSA-N CCCC(CCCC(C)=O)C(c(cc1-c2ccc(cc[n]3C(C)C)c3c2)cc2c1nccn2)=N Chemical compound CCCC(CCCC(C)=O)C(c(cc1-c2ccc(cc[n]3C(C)C)c3c2)cc2c1nccn2)=N LPIRIXGJDXJEFW-UHFFFAOYSA-N 0.000 description 1
- VITNZHFPDZMACK-UHFFFAOYSA-N CCCCCc(c(CC)c1)ccc1Br Chemical compound CCCCCc(c(CC)c1)ccc1Br VITNZHFPDZMACK-UHFFFAOYSA-N 0.000 description 1
- VVCGLICGHPPJDH-UHFFFAOYSA-N CCCCN(C)c1cc(B2OC(C)(C)C(C)(C)O2)ccc1C=N Chemical compound CCCCN(C)c1cc(B2OC(C)(C)C(C)(C)O2)ccc1C=N VVCGLICGHPPJDH-UHFFFAOYSA-N 0.000 description 1
- GGTPGGSAMDTDGO-UHFFFAOYSA-N CNC(CN(CC1)CCC1C(c1cccnc1)Nc(cc1-c2ccc(cc[n]3C)c3c2)cc2c1nccn2)=O Chemical compound CNC(CN(CC1)CCC1C(c1cccnc1)Nc(cc1-c2ccc(cc[n]3C)c3c2)cc2c1nccn2)=O GGTPGGSAMDTDGO-UHFFFAOYSA-N 0.000 description 1
- PAUFMURYKLMMOY-UHFFFAOYSA-N CNc(cc1)ncc1C(c1cccnc1)=O Chemical compound CNc(cc1)ncc1C(c1cccnc1)=O PAUFMURYKLMMOY-UHFFFAOYSA-N 0.000 description 1
- WTQIXBKDAKZURN-UHFFFAOYSA-N CNc1cc(-c2c3nccnc3cc([IH]C)c2)ccc1C=N Chemical compound CNc1cc(-c2c3nccnc3cc([IH]C)c2)ccc1C=N WTQIXBKDAKZURN-UHFFFAOYSA-N 0.000 description 1
- WHSVKONWIKGJBA-GKAPJAKFSA-N C[C@@H](c1cncc(C2=CC(C)N=C2)c1)N Chemical compound C[C@@H](c1cncc(C2=CC(C)N=C2)c1)N WHSVKONWIKGJBA-GKAPJAKFSA-N 0.000 description 1
- AKWBBLWUAVNQDE-UHFFFAOYSA-N C[n](c1c2)ncc1ccc2-c1cc(Cl)cc2c1nccn2 Chemical compound C[n](c1c2)ncc1ccc2-c1cc(Cl)cc2c1nccn2 AKWBBLWUAVNQDE-UHFFFAOYSA-N 0.000 description 1
- HCCNQCLCRDBAPR-UHFFFAOYSA-N C[n](cc1)c2c1ccc(-c1cc(N(Cc3cccnc3)c3ccccn3)cc3c1nccn3)c2 Chemical compound C[n](cc1)c2c1ccc(-c1cc(N(Cc3cccnc3)c3ccccn3)cc3c1nccn3)c2 HCCNQCLCRDBAPR-UHFFFAOYSA-N 0.000 description 1
- MTSRIZXTQTWECY-UHFFFAOYSA-N C[n](cc1)c2c1ccc(-c1cc(NC(c3ccn[s]3)c(cc3)cnc3OC)cc3c1nccn3)c2 Chemical compound C[n](cc1)c2c1ccc(-c1cc(NC(c3ccn[s]3)c(cc3)cnc3OC)cc3c1nccn3)c2 MTSRIZXTQTWECY-UHFFFAOYSA-N 0.000 description 1
- DEMRFSVCZBJTGR-UHFFFAOYSA-N C[n](cc1)c2c1ccc(-c1cc(NCC3NCCOC3)cc3c1nccn3)c2 Chemical compound C[n](cc1)c2c1ccc(-c1cc(NCC3NCCOC3)cc3c1nccn3)c2 DEMRFSVCZBJTGR-UHFFFAOYSA-N 0.000 description 1
- MNKSTGKJUWVHHR-UHFFFAOYSA-N C[n]1c2cc(-c3c4nccnc4cc(N(Cc4ccncc4)c4cnccc4)c3)ccc2cc1 Chemical compound C[n]1c2cc(-c3c4nccnc4cc(N(Cc4ccncc4)c4cnccc4)c3)ccc2cc1 MNKSTGKJUWVHHR-UHFFFAOYSA-N 0.000 description 1
- XIAGLCIWPFZUTJ-UHFFFAOYSA-N C[n]1c2cc(-c3c4nccnc4cc(NC(CC4)CCN4c4ncccn4)c3)ccc2cc1 Chemical compound C[n]1c2cc(-c3c4nccnc4cc(NC(CC4)CCN4c4ncccn4)c3)ccc2cc1 XIAGLCIWPFZUTJ-UHFFFAOYSA-N 0.000 description 1
- MZUHOFZPDUAMNB-UHFFFAOYSA-N C[n]1c2cc(-c3c4nccnc4cc(NC(c4cnn[n]4C)c(cc4)cnc4OC)c3)ccc2cc1 Chemical compound C[n]1c2cc(-c3c4nccnc4cc(NC(c4cnn[n]4C)c(cc4)cnc4OC)c3)ccc2cc1 MZUHOFZPDUAMNB-UHFFFAOYSA-N 0.000 description 1
- RLIBSSYBAWPJMR-UHFFFAOYSA-N C[n]1c2cc(-c3c4nccnc4cc(Nc4ncccc4)c3)ccc2cc1 Chemical compound C[n]1c2cc(-c3c4nccnc4cc(Nc4ncccc4)c3)ccc2cc1 RLIBSSYBAWPJMR-UHFFFAOYSA-N 0.000 description 1
- RQYSEHUBYKOZIH-KRWDZBQOSA-N C[n]1c2cc(-c3cc(C([C@@H]4CNCC4)=N)cc4c3cccn4)ccc2cc1 Chemical compound C[n]1c2cc(-c3cc(C([C@@H]4CNCC4)=N)cc4c3cccn4)ccc2cc1 RQYSEHUBYKOZIH-KRWDZBQOSA-N 0.000 description 1
- QXPVPVREWGZKIF-UHFFFAOYSA-N C[n]1c2cc(-c3cc(Cl)cc4c3nccn4)ccc2cc1 Chemical compound C[n]1c2cc(-c3cc(Cl)cc4c3nccn4)ccc2cc1 QXPVPVREWGZKIF-UHFFFAOYSA-N 0.000 description 1
- AIGZKTAURBDPHM-UHFFFAOYSA-N C[n]1c2cc(-c3cc(NC(C(CC4)CCN4C(CCN)=O)c4cccnc4)cc4c3nccn4)ccc2cc1 Chemical compound C[n]1c2cc(-c3cc(NC(C(CC4)CCN4C(CCN)=O)c4cccnc4)cc4c3nccn4)ccc2cc1 AIGZKTAURBDPHM-UHFFFAOYSA-N 0.000 description 1
- LSYIHGMYRVQUQS-UHFFFAOYSA-N C[n]1c2cc(-c3cc(NC(C4CCNCC4)c4cccnc4)cc4c3nccn4)ccc2cc1 Chemical compound C[n]1c2cc(-c3cc(NC(C4CCNCC4)c4cccnc4)cc4c3nccn4)ccc2cc1 LSYIHGMYRVQUQS-UHFFFAOYSA-N 0.000 description 1
- KVODKETZRXYRFR-UHFFFAOYSA-N C[n]1c2cc(-c3cc(NC(c4cc(OC)ncc4)c4cccnc4)cc4c3nccn4)ccc2cc1 Chemical compound C[n]1c2cc(-c3cc(NC(c4cc(OC)ncc4)c4cccnc4)cc4c3nccn4)ccc2cc1 KVODKETZRXYRFR-UHFFFAOYSA-N 0.000 description 1
- REYQUODTLKIAMI-UHFFFAOYSA-N C[n]1c2cc(-c3cc(NC(c4cnn[n]4C)c4cccnc4)cc4c3nccn4)ccc2cc1 Chemical compound C[n]1c2cc(-c3cc(NC(c4cnn[n]4C)c4cccnc4)cc4c3nccn4)ccc2cc1 REYQUODTLKIAMI-UHFFFAOYSA-N 0.000 description 1
- JRVCNIOPJCWASA-UHFFFAOYSA-N C[n]1c2cc(-c3cc(NCc(cc4)ccc4C#N)cc4c3nccn4)ccc2cc1 Chemical compound C[n]1c2cc(-c3cc(NCc(cc4)ccc4C#N)cc4c3nccn4)ccc2cc1 JRVCNIOPJCWASA-UHFFFAOYSA-N 0.000 description 1
- HEEBRASXFNXLKE-UHFFFAOYSA-N C[n]1c2cc(-c3cc(NCc4c[o]nc4)cc4c3nccn4)ccc2cc1 Chemical compound C[n]1c2cc(-c3cc(NCc4c[o]nc4)cc4c3nccn4)ccc2cc1 HEEBRASXFNXLKE-UHFFFAOYSA-N 0.000 description 1
- NHENREWNMHRWFE-UHFFFAOYSA-N C[n]1c2cc(-c3cc(NCc4ccnc(-c5c[n](C)nc5)c4)cc4c3nccn4)ccc2cc1 Chemical compound C[n]1c2cc(-c3cc(NCc4ccnc(-c5c[n](C)nc5)c4)cc4c3nccn4)ccc2cc1 NHENREWNMHRWFE-UHFFFAOYSA-N 0.000 description 1
- NGOSFRZQTIJUKL-UHFFFAOYSA-N C[n]1c2cc(-c3cc(NCc4nnc[nH]4)cc4c3nccn4)ccc2cc1 Chemical compound C[n]1c2cc(-c3cc(NCc4nnc[nH]4)cc4c3nccn4)ccc2cc1 NGOSFRZQTIJUKL-UHFFFAOYSA-N 0.000 description 1
- RXOUSLPYLVPQBS-UHFFFAOYSA-N C[n]1c2cc(-c3cc(O)cc4c3nccn4)ccc2cc1 Chemical compound C[n]1c2cc(-c3cc(O)cc4c3nccn4)ccc2cc1 RXOUSLPYLVPQBS-UHFFFAOYSA-N 0.000 description 1
- DMZVDSPQWHIGJP-UHFFFAOYSA-N C[n]1nncc1C(c1cccnc1)N Chemical compound C[n]1nncc1C(c1cccnc1)N DMZVDSPQWHIGJP-UHFFFAOYSA-N 0.000 description 1
- BIDLROYHTMGTHG-UHFFFAOYSA-N Cc(c1c2)c[s]c1ccc2-c1cc(NC(c2cnc[n]2C)c(cn2)ccc2OC)cc2c1nccn2 Chemical compound Cc(c1c2)c[s]c1ccc2-c1cc(NC(c2cnc[n]2C)c(cn2)ccc2OC)cc2c1nccn2 BIDLROYHTMGTHG-UHFFFAOYSA-N 0.000 description 1
- CHQFOAMSJOTUBA-UHFFFAOYSA-N Cc(cc1-c2cc([nH]cc3)c3cc2)cc2c1nccn2 Chemical compound Cc(cc1-c2cc([nH]cc3)c3cc2)cc2c1nccn2 CHQFOAMSJOTUBA-UHFFFAOYSA-N 0.000 description 1
- HBHJVZYFRWATDK-UHFFFAOYSA-N Clc(cc1-c2ccc(cc[n]3Cc4ccccc4)c3c2)cc2c1nccn2 Chemical compound Clc(cc1-c2ccc(cc[n]3Cc4ccccc4)c3c2)cc2c1nccn2 HBHJVZYFRWATDK-UHFFFAOYSA-N 0.000 description 1
- WVUFWPKBUOUFCL-UHFFFAOYSA-N Clc1cc(NC(C2CCNCC2)c2cccnc2)cc2c1nccn2 Chemical compound Clc1cc(NC(C2CCNCC2)c2cccnc2)cc2c1nccn2 WVUFWPKBUOUFCL-UHFFFAOYSA-N 0.000 description 1
- PWRBCZZQRRPXAB-UHFFFAOYSA-N Clc1cnccc1 Chemical compound Clc1cnccc1 PWRBCZZQRRPXAB-UHFFFAOYSA-N 0.000 description 1
- AHOYJNPJPHJWCI-UHFFFAOYSA-N N=C1N=C(C=CC(Br)=C2)C2=C1 Chemical compound N=C1N=C(C=CC(Br)=C2)C2=C1 AHOYJNPJPHJWCI-UHFFFAOYSA-N 0.000 description 1
- WGDHXHKTNGOFPW-QMMMGPOBSA-N N[C@@H](CC1)CN1c1ncccc1 Chemical compound N[C@@H](CC1)CN1c1ncccc1 WGDHXHKTNGOFPW-QMMMGPOBSA-N 0.000 description 1
- YCPJNNOPMDXOQH-UHFFFAOYSA-N N[I](C=C1)c2c1ccc(-c1cc(NCc3cc(C#N)ccc3)cc3c1nccn3)c2 Chemical compound N[I](C=C1)c2c1ccc(-c1cc(NCc3cc(C#N)ccc3)cc3c1nccn3)c2 YCPJNNOPMDXOQH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15001451 | 2015-05-13 | ||
| EP15460017.5 | 2015-05-13 | ||
| EP15001451.2 | 2015-05-13 | ||
| EP15460017 | 2015-05-14 | ||
| PCT/EP2016/000783 WO2016180536A1 (en) | 2015-05-13 | 2016-05-12 | Substituted quinoxaline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018515612A true JP2018515612A (ja) | 2018-06-14 |
| JP2018515612A5 JP2018515612A5 (enExample) | 2019-06-13 |
Family
ID=56081443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511333A Pending JP2018515612A (ja) | 2015-05-13 | 2016-05-12 | 置換キノキサリン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20180148429A1 (enExample) |
| EP (1) | EP3294729A1 (enExample) |
| JP (1) | JP2018515612A (enExample) |
| CN (1) | CN107635986A (enExample) |
| AU (1) | AU2016261031A1 (enExample) |
| CA (1) | CA2979302A1 (enExample) |
| IL (1) | IL254870A0 (enExample) |
| TW (1) | TW201713641A (enExample) |
| WO (1) | WO2016180536A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019528247A (ja) * | 2016-07-14 | 2019-10-10 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 二環式ヘテロアリール置換化合物 |
| WO2025084787A1 (ko) * | 2023-10-17 | 2025-04-24 | 가천대학교 산학협력단 | 신규 퀴녹살린 화합물, 이의 제조방법 및 이의 용도 |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190256499A1 (en) * | 2016-11-08 | 2019-08-22 | Merck Patent Gmbh | Substituted quinoxaline derivatives as inhibitors of pfkfb |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| WO2019065516A1 (ja) * | 2017-09-26 | 2019-04-04 | 日本曹達株式会社 | キノリン化合物および農園芸用殺菌剤 |
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| FI3768684T3 (fi) | 2018-03-22 | 2023-04-26 | Hoffmann La Roche | Oksatsiinimonoasyyliglyserolilipaasin (magl) estäjiä |
| WO2019236884A1 (en) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| MA53219B1 (fr) | 2018-08-13 | 2024-09-30 | F. Hoffmann-La Roche Ag | Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase |
| WO2020080979A1 (en) * | 2018-10-15 | 2020-04-23 | Gero Discovery Limited Liability Company | Pfkfb3 inhibitors and their uses |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CA3123215C (en) | 2018-12-19 | 2024-04-02 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with neuroprotective agents |
| CA3169412A1 (en) * | 2019-08-06 | 2021-02-11 | The University Of North Carolina At Chapel Hill | Rna-targeting ligands, compositions thereof, and methods of making and using the same |
| CN110698418B (zh) * | 2019-09-11 | 2022-07-01 | 广西师范大学 | 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用 |
| CR20220104A (es) | 2019-09-12 | 2022-04-20 | Hoffmann La Roche | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl |
| EP4034239A1 (en) | 2019-09-23 | 2022-08-03 | F. Hoffmann-La Roche AG | Heterocyclic compounds |
| IL298005A (en) * | 2020-05-08 | 2023-01-01 | Merck Patent Gmbh | Tricyclic heterocycles compounds, their preparation and pharmaceutical compositions containing them |
| BR112022026385A2 (pt) * | 2020-07-23 | 2023-01-31 | Merck Patent Gmbh | Heterociclos tricíclicos |
| WO2022043284A1 (en) | 2020-08-26 | 2022-03-03 | F. Hoffmann-La Roche Ag | Heterocyclic compounds useful as magl inhibitors |
| PE20231372A1 (es) | 2020-09-03 | 2023-09-07 | Hoffmann La Roche | Compuestos heterociclicos |
| AR124136A1 (es) | 2020-11-25 | 2023-02-15 | Servier Pharmaceuticals Llc | Nuevos compuestos orgánicos |
| BR112023025008A2 (pt) * | 2021-06-02 | 2024-04-30 | Univ North Carolina Chapel Hill | Ligantes de alvo de rna, suas composições e métodos de fabricação e uso dos mesmos |
| CN119301113A (zh) | 2022-06-24 | 2025-01-10 | 豪夫迈·罗氏有限公司 | 作为magl抑制剂的新的杂环羰基环状化合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011103557A1 (en) * | 2010-02-22 | 2011-08-25 | Advanced Cancer Therapeutics, Llc | Small molecule inhibitors of pfkfb3 and glycolytic flux and their methods of use as anti-cancer therapeutics |
| JP2013028588A (ja) * | 2011-06-24 | 2013-02-07 | Ishihara Sangyo Kaisha Ltd | 有害生物防除剤 |
| JP2015512398A (ja) * | 2012-03-29 | 2015-04-27 | アドヴァンスト キャンサー セラピューティクス エルエルシーAdvanced Cancer Therapeutics, LLC | Pfkfb2阻害剤および抗癌治療法としての使用方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5633218A (en) * | 1995-05-24 | 1997-05-27 | E. I. Du Pont De Nemours And Company | Herbicidal benzodioxoles and benzodioxanes |
| US20140128392A1 (en) * | 2009-03-19 | 2014-05-08 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
-
2016
- 2016-05-12 AU AU2016261031A patent/AU2016261031A1/en not_active Abandoned
- 2016-05-12 JP JP2018511333A patent/JP2018515612A/ja active Pending
- 2016-05-12 CA CA2979302A patent/CA2979302A1/en not_active Abandoned
- 2016-05-12 TW TW105114781A patent/TW201713641A/zh unknown
- 2016-05-12 WO PCT/EP2016/000783 patent/WO2016180536A1/en not_active Ceased
- 2016-05-12 EP EP16725031.5A patent/EP3294729A1/en not_active Withdrawn
- 2016-05-12 US US15/572,470 patent/US20180148429A1/en not_active Abandoned
- 2016-05-12 CN CN201680027578.3A patent/CN107635986A/zh active Pending
-
2017
- 2017-10-03 IL IL254870A patent/IL254870A0/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011103557A1 (en) * | 2010-02-22 | 2011-08-25 | Advanced Cancer Therapeutics, Llc | Small molecule inhibitors of pfkfb3 and glycolytic flux and their methods of use as anti-cancer therapeutics |
| JP2013028588A (ja) * | 2011-06-24 | 2013-02-07 | Ishihara Sangyo Kaisha Ltd | 有害生物防除剤 |
| JP2015512398A (ja) * | 2012-03-29 | 2015-04-27 | アドヴァンスト キャンサー セラピューティクス エルエルシーAdvanced Cancer Therapeutics, LLC | Pfkfb2阻害剤および抗癌治療法としての使用方法 |
Non-Patent Citations (1)
| Title |
|---|
| BIOORGANIC & MEDICINAL CHEMISTRY, vol. 22, JPN6020001673, 2014, pages 1029 - 1039, ISSN: 0004196256 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019528247A (ja) * | 2016-07-14 | 2019-10-10 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 二環式ヘテロアリール置換化合物 |
| JP7058256B2 (ja) | 2016-07-14 | 2022-04-21 | ブリストル-マイヤーズ スクイブ カンパニー | 二環式ヘテロアリール置換化合物 |
| WO2025084787A1 (ko) * | 2023-10-17 | 2025-04-24 | 가천대학교 산학협력단 | 신규 퀴녹살린 화합물, 이의 제조방법 및 이의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201713641A (zh) | 2017-04-16 |
| CA2979302A1 (en) | 2016-11-17 |
| IL254870A0 (en) | 2017-12-31 |
| EP3294729A1 (en) | 2018-03-21 |
| WO2016180536A1 (en) | 2016-11-17 |
| CN107635986A (zh) | 2018-01-26 |
| US20180148429A1 (en) | 2018-05-31 |
| AU2016261031A1 (en) | 2017-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515612A (ja) | 置換キノキサリン誘導体 | |
| JP6586104B2 (ja) | 5−置換インダゾール−3−カルボキサミドならびにその調製および使用の方法 | |
| CN106170486B (zh) | 新吲唑甲酰胺、其制备方法、包含其的药物制剂及其用于制备药物的用途 | |
| CN107501275B (zh) | 可用作atr激酶抑制剂的化合物 | |
| WO2020239077A1 (zh) | 含氮杂环类衍生物调节剂、其制备方法和应用 | |
| CN103998042B (zh) | Pi3k的活性或功能的抑制剂的应用 | |
| KR20210111252A (ko) | Irak 분해제 및 이의 용도 | |
| CN107474050B (zh) | 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮化合物 | |
| JP2019081786A (ja) | Trkaキナーゼ阻害剤としてのn−ピロリジニル、n’−ピラゾリル尿素、チオ尿素、グアニジン、およびシアノグアニジン化合物 | |
| CN110036004A (zh) | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 | |
| EP3560924A1 (de) | Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren | |
| CN101321756A (zh) | 用作细胞周期蛋白依赖性激酶抑制剂的新的吡唑并嘧啶化合物 | |
| CN101772500A (zh) | 作为蛋白质激酶抑制剂的咪唑并吡嗪 | |
| CN102675282B (zh) | 取代的喹啉化合物及其使用方法和用途 | |
| CN105452257A (zh) | 新型稠合嘧啶化合物或其盐 | |
| CN114907338B (zh) | 含氮多环稠环类化合物,其药物组合物、制备方法和用途 | |
| CN113423707A (zh) | Erk抑制剂及其用途 | |
| JP2021504380A (ja) | Pde1阻害剤としての置換フラノピリミジン化合物 | |
| JP2021516674A (ja) | 5−ヘテロアリール置換イミダゾール−3−カルボキサミドならびにその調製および使用の方法 | |
| CA3078942A1 (en) | Pyrrolotriazine compounds and methods of inhibiting tam kinases | |
| EP4667458A1 (en) | Pharmaceutical composition for treatment of cancer, comprising sos1 inhibitor and anticancer drug | |
| TW201710250A (zh) | 經取代之喹喏啉衍生物 | |
| WO2021233236A1 (zh) | 取代的杂芳基化合物及其组合物和用途 | |
| KR20250167680A (ko) | Irak 분해제 및 이의 용도 | |
| HK40012363A (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190508 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190508 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200123 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200128 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200901 |